Biomarker-based prediction of sinus rhythm in atrial fibrillation patients: the EAST-AFNET 4 biomolecule study.

Autor:	Fabritz L; University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany.; Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Martinistr. 52, Hamburg 20246, Germany.; German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Martinistr. 52, Hamburg 20246, Germany.; Atrial Fibrillation NETwork (AFNET), Mendelstr. 11, 48149 Münster, Germany.; Institute of Cardiovascular Sciences, Wolfson Drive, University of Birmingham, B15 2TT Birmingham, UK.; MAESTRIA Consortium, European Union's Horizon 2020 research and innovation programme, agreement number 965286, Sorbonne Université, Paris, France., Al-Taie C; University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany.; Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Martinistr. 52, Hamburg 20246, Germany.; German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Martinistr. 52, Hamburg 20246, Germany.; MAESTRIA Consortium, European Union's Horizon 2020 research and innovation programme, agreement number 965286, Sorbonne Université, Paris, France., Borof K; Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Martinistr. 52, Hamburg 20246, Germany., Breithardt G; Atrial Fibrillation NETwork (AFNET), Mendelstr. 11, 48149 Münster, Germany.; Department of Cardiology II (Electrophysiology), University Hospital Münster, Germany., Camm AJ; Clinical Sciences, St George's University, London, UK., Crijns HJGM; Department of Cardiology, University Hospital Maastricht, Maastricht, The Netherlands., Roth Cardoso V; Institute of Cardiovascular Sciences, Wolfson Drive, University of Birmingham, B15 2TT Birmingham, UK.; MRC Health Data Research UK (HDR), Midlands Site, Birmingham, UK.; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK., Chua W; Institute of Cardiovascular Sciences, Wolfson Drive, University of Birmingham, B15 2TT Birmingham, UK.; MAESTRIA Consortium, European Union's Horizon 2020 research and innovation programme, agreement number 965286, Sorbonne Université, Paris, France., van Elferen S; University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany.; Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Martinistr. 52, Hamburg 20246, Germany.; Computational and Systems Biology at Hamburg University, Germany., Eckardt L; Atrial Fibrillation NETwork (AFNET), Mendelstr. 11, 48149 Münster, Germany.; Department of Cardiology II (Electrophysiology), University Hospital Münster, Germany., Gkoutos G; University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany.; Institute of Cardiovascular Sciences, Wolfson Drive, University of Birmingham, B15 2TT Birmingham, UK.; MAESTRIA Consortium, European Union's Horizon 2020 research and innovation programme, agreement number 965286, Sorbonne Université, Paris, France.; MRC Health Data Research UK (HDR), Midlands Site, Birmingham, UK.; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK., Goette A; Atrial Fibrillation NETwork (AFNET), Mendelstr. 11, 48149 Münster, Germany.; MAESTRIA Consortium, European Union's Horizon 2020 research and innovation programme, agreement number 965286, Sorbonne Université, Paris, France.; Department of Cardiology and Intensive Care Medicine, St. Vincenz Hospital, Paderborn, Germany.; Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany., Guasch E; Hospital Clinic de Barcelona, Institute of Biomedical Research August Pi Sunyer (IDIBAPS), Hospital Clinic, CIBERCV, University of Barcelona, Catalonia, Spain., Hatem S; MAESTRIA Consortium, European Union's Horizon 2020 research and innovation programme, agreement number 965286, Sorbonne Université, Paris, France.; Department of Cardiology, Sorbonne Université, Faculté de médecine UPMC, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France., Metzner A; Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Martinistr. 52, Hamburg 20246, Germany., Mont L; Hospital Clinic de Barcelona, Institute of Biomedical Research August Pi Sunyer (IDIBAPS), Hospital Clinic, CIBERCV, University of Barcelona, Catalonia, Spain., Murukutla VA; University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany.; German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Martinistr. 52, Hamburg 20246, Germany.; MAESTRIA Consortium, European Union's Horizon 2020 research and innovation programme, agreement number 965286, Sorbonne Université, Paris, France., Obergassel J; University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany.; Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Martinistr. 52, Hamburg 20246, Germany.; MAESTRIA Consortium, European Union's Horizon 2020 research and innovation programme, agreement number 965286, Sorbonne Université, Paris, France., Rillig A; Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Martinistr. 52, Hamburg 20246, Germany.; German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Martinistr. 52, Hamburg 20246, Germany., Sinner MF; Department of Medicine I, University Hospital Munich, Ludwig Maximilian University of Munich (LMU), Munich, Germany.; German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany., Schnabel RB; Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Martinistr. 52, Hamburg 20246, Germany.; German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Martinistr. 52, Hamburg 20246, Germany.; Atrial Fibrillation NETwork (AFNET), Mendelstr. 11, 48149 Münster, Germany., Schotten U; Atrial Fibrillation NETwork (AFNET), Mendelstr. 11, 48149 Münster, Germany.; MAESTRIA Consortium, European Union's Horizon 2020 research and innovation programme, agreement number 965286, Sorbonne Université, Paris, France.; Department of Physiology, Maastricht University, Maastricht, The Netherlands., Sommerfeld LC; University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany.; German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Martinistr. 52, Hamburg 20246, Germany.; Institute of Cardiovascular Sciences, Wolfson Drive, University of Birmingham, B15 2TT Birmingham, UK.; MAESTRIA Consortium, European Union's Horizon 2020 research and innovation programme, agreement number 965286, Sorbonne Université, Paris, France., Wienhues-Thelen UH; Roche Diagnostics, Penzberg, Germany., Zapf A; German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Martinistr. 52, Hamburg 20246, Germany.; Atrial Fibrillation NETwork (AFNET), Mendelstr. 11, 48149 Münster, Germany.; Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany., Zeller T; University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany.; Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Martinistr. 52, Hamburg 20246, Germany.; German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Martinistr. 52, Hamburg 20246, Germany., Kirchhof P; Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Martinistr. 52, Hamburg 20246, Germany.; German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Martinistr. 52, Hamburg 20246, Germany.; Atrial Fibrillation NETwork (AFNET), Mendelstr. 11, 48149 Münster, Germany.; Institute of Cardiovascular Sciences, Wolfson Drive, University of Birmingham, B15 2TT Birmingham, UK.; MAESTRIA Consortium, European Union's Horizon 2020 research and innovation programme, agreement number 965286, Sorbonne Université, Paris, France.
Jazyk:	angličtina
Zdroj:	European heart journal [Eur Heart J] 2024 Dec 16; Vol. 45 (47), pp. 5002-5019.
DOI:	10.1093/eurheartj/ehae611
Abstrakt:	Background and Aims: In patients with atrial fibrillation (AF), recurrent AF and sinus rhythm during follow-up are determined by interactions between cardiovascular disease processes and rhythm control therapy. Predictors of attaining sinus rhythm at follow-up are not well known. Methods: To quantify the interaction between cardiovascular disease processes and rhythm outcomes, 14 biomarkers reflecting AF-related cardiovascular disease processes in 1586 patients in the EAST-AFNET 4 biomolecule study (71 years old, 45% women) were quantified at baseline. Mixed logistic regression models including clinical features were constructed for each biomarker. Biomarkers were interrogated for interaction with early rhythm control. Outcome was sinus rhythm at 12 months. Results were validated at 24 months and in external datasets. Results: Higher baseline concentrations of three biomarkers were independently associated with a lower chance of sinus rhythm at 12 months: angiopoietin 2 (ANGPT2) (odds ratio [OR] .76 [95% confidence interval .65-.89], P < .001), bone morphogenetic protein 10 (BMP10) (OR .83 [.71-.97], P = .017), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) (OR .73 [.60-.88], P < .001). Analysis of rhythm at 24 months confirmed the results. Early rhythm control interacted with the predictive potential of NT-proBNP (Pinteraction = .033). The predictive effect of NT-proBNP was reduced in patients randomized to early rhythm control (usual care: OR .64 [.51-.80], P < .001; early rhythm control: OR .90 [.69-1.18], P = .453). External validation confirmed that low concentrations of ANGPT2, BMP10, and NT-proBNP predict sinus rhythm during follow-up. Conclusions: Low concentrations of ANGPT2, BMP10, and NT-proBNP identify patients with AF who are likely to attain sinus rhythm during follow-up. The predictive ability of NT-proBNP is attenuated in patients receiving rhythm control. (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu